排序方式: 共有38条查询结果,搜索用时 15 毫秒
1.
我院1998~2004年共收治因各种心律失常而服用胺碘酮(AMD)致甲亢患12例,其治疗与预后同一般甲亢殊多不同,现报告并分析如下。 相似文献
2.
3.
瘦素与胰岛素抵抗及糖代谢异常的关系 总被引:4,自引:0,他引:4
当供给人体的热量多于消耗量而以脂肪形式贮存在体内 ,使人体重量超过标准体重的 2 0 %时称为肥胖。肥胖患者常出现胰岛素抵抗 (IR) ,血浆胰岛素增高 ,外周组织对胰岛素的敏感性下降。研究表明 ,肥胖是糖代谢异常的重要诱发因素 ,与 2型糖尿病的发生相关。近年来发现 ,肥胖基因的蛋白质产物瘦素 (leptin)能调节体重与能量代谢 ,但与IR及糖代谢异常的关系仍不十分清楚 ,本研究测定 84例受检者血清瘦素含量及其它有关指标 ,探讨瘦素与IR及糖代谢异常的关系。一、对象和方法1.对象 :84例受检者以往未发现患有糖尿病、甲状腺等内分… 相似文献
4.
5.
6.
Objective : To investigate the clinical value of microcirculation dredging therapy (MD for short) for the type 2 diabetic nephropathy patients (DN). Method : 94 early stage DN patients were divided into conventional group (C Group)and dredging treatment group (T Group). For the C Group, the conventional treatment method of controlling blood glucose, blood pressure and blood lipid was applied, and for the T Group ,in addition to the conventional treatment as applied to the C Group, Dextran 40 Glucose injection and mailuoning was injected by intravenous drip, with concurrent oral administration of acetylsalicylic acid enterosoluble tables. Both groups were treated for a period of six minths. Results: Determination of both groups showed after the treatment as compared with those before the treatment, but T Group showedmore apparent decrease (P<0.05-0. 001), the T Group showed apparently more reduction in fibrinogen(Fg) and platelet a-granule membrane protein (GMP -140) (P<0. 001) as compared with the C Group (P< 0. 05-0. 001) ;after the treatment, the blood glucose, blood pressure and blood lipid were well controlledin both groups (P<0. 05-0. 001), with no substantial difference between the two groups (P>0.05). Theresults of regression analysis showed that there was a positive correlation between platelet GMP-140andurinary albumin (UAIb) (r=0. 5433, P<0.01). Conclusion: For early stage DN patients, the MD therapymay further improve the renal function while controlling he blood glucose, blood pressure and blood lipid. 相似文献
7.
甘精胰岛素联合口服降糖药治疗2型糖尿病磺脲类继发性失效临床观察 总被引:2,自引:0,他引:2
目的:探讨甘精胰岛素联合口服降糖药物(拜糖苹或二甲双胍)治疗继发性磺脲类药物失效的2型糖尿病的短期疗效。方法:46例继发性磺脲类药物失效的2型糖尿病患者随机分成两组,A组使用甘精胰岛素加拜糖苹或二甲双胍,B组使用中效胰岛素加拜糖苹或二甲双胍。所有患者均于治疗前、治疗后12周测定空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbAte)。结果:两组治疗3个月后,FBG、2hBG、HbA。。均较治疗前明显降低,对于空腹血糖的控制A组明显优于B组,有统计学意义(P<0.05),且A组低血糖发生率明显低于B组(P<0.05)。结论:甘精胰岛素联合口服降糖药治疗继发性磺脲类药物失效的2型糖尿病患者,可以良好地控制高血糖,且低血糖发生率低,安全而有效。 相似文献
8.
糖代谢异常患者血清瘦素含量的临床研究 总被引:2,自引:0,他引:2
目的 观察糖代谢异常患者血清瘦素含量。方法 将131例糖代谢异常患者按病情分为糖耐量减退组(减退组)和2型糖尿病组(糖尿病组),并以41名健康人作为对照组,测定受检者血清瘦素含量及其他有关指标,在瘦素及其相关指标之间做多因素回归分析。结果 减退组和糖尿病组空腹瘦素(F-Lp)、空腹胰岛素(FINS)、体重指数(BMI)、腰/臀比值(WHR)均高于对照组(P<0.05-0.001),但减退组和糖尿病组比较,差异无显著性(P>0.05)。减退组空腹血糖(FBG)、糖化血红蛋白(HbA1C)均高于对照组,低于糖尿病组(P<0.05-0.001);糖代谢异常患者血糖、病程与瘦素含量不相关,BMI、WHR和FINS水平与瘦素含量独立相关。结论 糖代谢异常患者血糖与血清瘦素含量无相关性,超重肥胖、脂肪分布异常和高胰岛素血症是影响血清瘦素含量的主要因素。 相似文献
9.
10.